Been looking at this Florida cannabis play and there's actually some interesting dynamics worth paying attention to. Back in 2024, Florida had Amendment 3 on the ballot for recreational legalization, and if you're tracking this space, you know how significant that market could be. We're talking about the third-largest state by population here, so the upside for cannabis stocks to buy was pretty substantial if that vote went through.

The thing is, even before full legalization, Florida's medical cannabis market had been growing but the growth rate was slowing. A lot of people just weren't bothering with the medical card process because of costs and friction. Once recreational access becomes easier, you'd expect way more casual users to actually make purchases legally. That's the thesis anyway.

Now, I get why people are skeptical about cannabis stocks. It's still Schedule I federally, which feels backwards when you've got 24+ states allowing recreational use. But the trend is pretty clear - more states keep legalizing every year, and eventually the federal side has to catch up. If you can stomach some volatility, the risk-reward setup is interesting.

So which plays were positioned best? Trulieve was the obvious one - they're the largest dispensary in Florida with like 127 locations and actually bankrolled the legalization push themselves. That tells you something about their conviction. Their 2023 numbers showed a $527 million net loss, which sounds brutal, but they were also expanding footprint by 10% and moving into new states. Analysts were pricing in a 53% upside target back then.

Then there's Verano Holdings, which owns the MÜV brand - second-largest in Florida with 74 locations. What caught my attention was they actually cut their losses in half in 2023 while Trulieve's doubled. Revenue was up 7% year-over-year and gross profit up 12%. Florida specifically showed an 11% sequential sales increase for them. The upside target was around 86% for Verano.

Third one worth looking at was Ayr Wellness - they had 64 locations in Florida, which represented 70% of their total footprint. Their 2023 revenue hit $463.6 million, up 10%, and they cut net losses by more than half. They were also getting creative with product innovation and premium edibles. The valuation was cheaper here with a 55% target upside, which made it interesting for smaller position sizes.

The real question for cannabis stocks to buy was whether you believed in the legalization thesis and federal de-scheduling eventually happening. If you did, these three had meaningful exposure to what could be a transformational market. The Florida vote was basically a catalyst, and the companies had already positioned themselves accordingly. Whether you're bullish or cautious on the sector, understanding these plays and the market dynamics was pretty essential for anyone tracking this space.